Table 2.
Number and survival outcomes of patients from each subgroup according to DID in elderly DLBCL patients (age ≥ 70 years)
| DID (mg/m2/wk) | No. of patients subgroup (%) |
2-Year PFS/OS rate (%) according to DID subgroup in aged ≥ 70 yr |
||
|---|---|---|---|---|
| Age < 70 yr | Age ≥ 70 yr | 2-Year PFS rate | 2-Year OS rate | |
| (a) 6.7 < DID ≤ 8.3 | 5 (1.4) | 5 (6.0) | 30.0 | 20.0 |
| (b) 8.3 < DID ≤ 10.0 | 3 (0.9) | 5 (6.0) | 40.0 | 60.0 |
| (c) 10.0 < DID ≤ 11.7 | 6 (1.7) | 8 (9.6) | 85.7 | 75.0 |
| (d) 11.7 < DID ≤ 13.4 | 33 (9.5) | 35 (42.2) | 61.1 | 50.4 |
| (e) 13.4 < DID ≤ 15.0 | 36 (10.3) | 9 (10.8) | 66.7 | 88.9 |
| (f) 15.0 < DID ≤ 16.7 | 266 (76.2) | 21 (25.3) | 63.8 | 66.7 |
p-value for 2-year PFS rate: (a+b) vs. (c+d+e+f)=0.036; (a) vs. (b)=0.271; (c) vs. (d)=0.362; (c) vs. (e)=0.462; (c) vs. (f)=0.392; (d) vs. (e)=0.782; (d) vs. (f)=0.913; (e) vs. (f)=0.815. p-value for 2-year OS rate: (a+b) vs. (c+d+e+f)=0.031; (a) vs. (b)=0.174; (c) vs. (d)=0.216; (c) vs. (e)=0.577; (c) vs. (f)=0.859; (d) vs. (e)=0.065; (d) vs. (f)=0.103; (e) vs. (f)=0.637. DID, dose intensity of doxorubicin; DLBCL, diffuse large B cell lymphoma; PFS, progression-free survival; OS, overall survival.